prediabetes

About Topics

Topics include original Beta Cells in Diabetes content, as well as expert-selected resources chosen by our Editorial Board.

Home › Prediabetes

Can Current Drug Therapy Prevent Beta Cell Failure and Bring Treatment Durability in T2DM?

Posted July 20, 2011 by John L. Leahy, MD
Tags: , , , , , , ,

A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability.

Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus.

Leahy, Jack L; Hirsch, Irl B; Peterson, Kevin A; Schneider, Doron
The Journal of clinical endocrinology and metabolism; 2010 Sep;95(9):4206-16. PMID: 20739389;
Category: Pathophysiology;
Tags: , , , , , , , ,

Family Medicine View On Case 1: Pre-Diabetes

Posted August 1, 2010 by Kevin A. Peterson, MD, MPH
Tags: , , , ,

Do you recognize this patient?  I have seen him in my office, or a person just like him. The Center for Disease Control (CDC, HHS) estimates that 57 million people in the U.S. have pre-diabetes.

New Concepts, Research and Therapies: A Conversation

Tags: , , , , , , , , ,

Doron Schneider, MD, a leading primary care physician and Jack Leahy, MD, a world-renowned beta cell researcher, discuss the new concepts, current research and therapies. (48:08)

Beta Cell Pathophysiology and Its Relevance to Primary Care

Tags: ,

A leading primary care physician and a world-renowned beta cell researcher discuss why it is important for primary care doctors to understand the role of beta cells in type 2 diabetes. (13:53)

FAQ: Are there tests that primary care physicians can use to gauge beta cell sensitivity or other measures of disease progression?

Tags: ,

Frequently asked questions for the primary care community, excerpted from a conversation between a leading primary care physician and a world-renowned beta cell researcher. (1:07)

FAQ: What is happening to pancreatic beta cells in people with pre-diabetes?

Tags: ,

Frequently asked questions for the primary care community, excerpted from a conversation between a leading primary care physician and a world-renowned beta cell researcher. (2:30)

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Buchanan, Thomas A; Xiang, Anny H; Peters, Ruth K; Kjos, Siri L; Marroquin, Aura; Goico, Jose; Ochoa, Cesar; Tan, Sylvia; Berkowitz, Kathleen; Hodis, Howard N; Azen, Stanley P
Diabetes; 2002 Sep;51(9):2796-803. PMID: 12196473;
Category: Interventions / GLP-1s;
Tags: , , ,

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Gerstein, H C; Yusuf, S; Bosch, J; Pogue, J; Sheridan, P; Dinccag, N; Hanefeld, M; Hoogwerf, B; Laakso, M; Mohan, V; Shaw, J; Zinman, B; Holman, R R
Lancet; 2006 Sep 23;368(9541):1096-105. PMID: 16997664;
Category: Interventions / Thiazolidinediones - TZDs;
Tags: , , ,

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.

Buchanan, T A; Xiang, A H; Peters, R K; Kjos, S L; Berkowitz, K; Marroquin, A; Goico, J; Ochoa, C; Azen, S P
Diabetes; 2000 May;49(5):782-8. PMID: 10905487;
Category: Interventions / Thiazolidinediones - TZDs;
Tags: , ,
  • Page 1 of 3
  •  
  • Next
|